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Breast cancera b s t r a c t
Plasma estrogen measurement with use of radioimmunoassays has been instrumental in the develop-
ment of aromatase inhibitors for endocrine therapy of postmenopausal breast cancer. However, due to
low plasma estrogen concentrations in postmenopausal women, direct radioimmunoassays lack the sen-
sitivity required. While certain laboratories have developed highly sensitive assays for research purposes
revealing plasma estrogen suppression consistent with results from tracer studies, such assays are time
and labor-consuming due to need for pre-analytical chromatographic puriﬁcation, sample concentration
and sometimes conversion of precursors to products. While novel chromatographic methods involving
mass spectrometry analysis are likely to replace such radioimmunoassays in the future, so far a limited
number of laboratories have developed suitable assays with a detection limit (around 1 pM) that is
required for analyzing plasma estrogen levels in patients during treatment with potent aromatase
inhibitors.
 2014 The Author. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
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While the history of endocrine therapy in breast cancer started
more than a century ago, the scientiﬁc rationale arose with the dis-
covery of [1] and conﬁrmation of the predictive value of [2] the
estrogen receptor (today known as ERa). In parallel, introduction
of what was known at that time as an adrenotoxic antiepileptic,
aminoglutethimide, in an attempt to achieve a ‘‘medical adrenalec-
tomy’’ [3], indirectly led to introduction of aromatase inhibition as
a successful endocrine therapy for postmenopausal women. While
clinically efﬁcient [4], subsequent studies by the Hershey grouprevealed sustained androgen production, despite estrogen suppres-
sion [5], a question solved when tracer studies [6] revealed that
aminoglutethimide directly inhibited peripheral aromatization of
androstenedione into estrone (E1). The discovery that aminoglu-
tethimide executed its anti-tumor efﬁcacy through aromatase inhi-
bition had profound inﬂuence on subsequent development of
endocrine therapy for breast cancer. While effective, aminogluteth-
imide treatment was associated with substantial side effects [7],
for which reason much efforts were placed on developing novel,
less toxic agents (see Ref. [8]). Importantly, the successful imple-
mentation of aromatase inhibition as a major endocrine for breast
cancer, from which more than a million breast cancer women
around the world currently are beneﬁtting, had not been possible
without these careful translational studies applying sensitive
radioimmunoassay’s, in concert with tracer studies, to deﬁne the
P.E. Lønning / Steroids 99 (2015) 26–31 27pharmacological mechanisms of action of aminoglutethimide and,
thus, aromatase inhibition as a useful endocrine treatment option
in breast cancer.
2. Tracer studies
While tracer studies and plasma estrogen assessment in concert
conﬁrmed aminoglutethimide to act as a potent aromatase inhibi-
tor in vivo [9], plasma estrogen radioimmunoassay’s lacked the
sensitivity to detect estrogen suppression >90%, which was what
to expect based on the tracer results. Thus, direct assessment of
in vivo aromatase inhibition by tracer studies were considered to
be the ‘‘gold standard’’. With new aromatase inhibitor compounds
in development, in collaboration with Professor Mitch Dowsett and
his team, we initiated a program for in vivo assessment of aroma-
tase inhibition. Using an HPLC method to separate estrogen metab-
olites [10], we developed an assay allowing assessment of in vivo
aromatase inhibition with an average detection limit >99.1%
[11–18]. The results are depicted in Table 1; in brief, while most
compounds (the so-called 1st and 2nd generation compounds)
caused in vivo aromatase inhibition <90%, the three 3rd generation
compounds; the steroidal inhibitor exemestane, as well as the
non-steroidal compounds anastrozole and letrozole, each caused
on average >98% aromatase inhibition. Most importantly; these
endocrine results were paralleled by clinical ﬁndings; while the
1st and 2nd generation compounds in general revealed clinical efﬁ-
cacy similar to tamoxifen [8], the three 3rd generation compounds
revealed superiority, also with respect to clinical efﬁcacy, and are
today used as routine endocrine therapy for postmenopausal
women in the adjuvant setting [19].
3. Plasma estrogen measurements in relation to treatment with
aromatase inhibitors
The results from in vivo tracer studies, in concert with the
results from large randomized studies, underline the imperative
of maximal aromatase inhibition for optimal clinical efﬁcacy. Thus,
while randomized studies revealed superiority for third-generation
aromatase inhibitors as compared to tamoxifen [19], in contrast
ﬁrst-and second-generation compounds were found of similar efﬁ-
cacy, but not superior, as compared to conventional therapy [8,20].
Tracer studies however are laborious and expensive to conduct and
may be applied to small patient groups only. Thus, there is a need
for simpler methods, like plasma estrogen measurement.
A key problem relates to low plasma estrogen levels in post-
menopausal women, in particular when on aromatase inhibitorTable 1
In vivo aromatase inhibition by different drugs evaluated in the clinical setting.
Drug Dose
First/second generation compounds
Aminoglutethimide (AG) 1000 mg daily
Roglethimide 400/800/1600 mg daily
Fadrozole 2 mg/4 mg daily
Formestane* 125 mg/250 mg daily
Formestane* 250 mg/500 mg i.m./2 w
Formestane* 500 mg i.m./w
Formestane + AG 500 mg i.m./w 1000 mg daily
Third-generation compounds
Exemestane 25 mg daily
Anastrozole 1 mg daily
Anastrozole 10 mg daily
Anastrozole 1 mg daily
Letrozole 2.5 mg daily
* Formestane = 4-hydroxyandrostenedione.
** Administered as 125 mg b.i.d.
*** Administered as 250 mg once daily.therapy. Taking into account plasma levels of estradiol (E2), E1
and estrone sulfate (E1S) to be in the 15–20 pM, 70–80 pM and
4–500 pM ranges, respectively [21], the assays need sensitivity
limits of a few pM to detect potential suppression >98%. Develop-
ing highly sensitive radioimmunoassays with a detection limit of
about 1 pg/ml (3.7 pM), the Herhsey group revealed signiﬁcant dif-
ferences with respect to plasma estrogen suppression between the
second-generation aromatase inhibitor CGS16949A [22] and
letrozole [23]. Notably, as for both studies the difference in plasma
estrogen suppression was corroborated by similar ﬁndings with
respect to suppression of urinary estrogen secretion.
A problem related to use of 3H-labelled standards in radioimmu-
noassays relates to the limited speciﬁc activity of these standards
(in the 50–160 mCi/mmol range). A higher speciﬁc activity may be
achieved with use of 125I-labelled compounds (speciﬁc activity in
the 2000 Ci/mmol range). The ﬁrst sensitive 125I-based RIA for E2
measurement in patients treated with aromatase inhibitors was
developed by Professor Mitch Dowsett at the Royal Marsden Hospi-
tal [24] and subsequently used to measure plasma E2 suppression
with different aromatase inhibitors [25–30]. Some years later,
learning this assay for E2 measurement, we used the same 125I-E2
standard and E2 antibody developing a highly sensitive assay for
plasma E1S measurement. The procedure involved taking the sam-
ples through multiple puriﬁcation steps (Fig. 1), hydrolysis and
ﬁnally conversion of unconjugated E1 into E2 [31].
Taking this approach further, we improved our assay, allowing
E1 as well as E1S to be converted into E2, each steroid to be mea-
sured with the same 125I-E2 assay (Table 2). The approach involved
adding minor amounts of 3H E2 as well as 3H E1 and 3H E1S for
recovery standard including correction of the ﬁnal results. As for
this assay, we achieved a detection limit of 0.67 pM for E2,
1.14 pM for E1 and 0.55 pM for E1S [32], a signiﬁcant improvement
as compared to our earlier 3H-based methods [33]. Applying this
assay to patients on treatment with anastrozole versus letrozole
[18], we recorded a mean suppression of plasma E2 of 92.8% versus
95.2%, for E1 96.3% versus 98.8%, and for E1S 95.3% versus 98.9%,
respectively [34]. It should be noted however that, even with this
sensitive assay, 5 out of 12 patients had plasma levels of E2 below
detection limit during anastrozole treatment; corresponding ﬁg-
ures for letrozole was as high as 11 out of 12 [34].
Another interesting approach was taken by Dr. Klein and her
teamwho used an ultrasensitive recombinant cell bioassay to mea-
sure estrogen levels in patients on treatment with letrozole [35];
this approach is discussed in detail in another paper in this issue.
A particular problem relates to plasma estrogen measurement






























Fig. 1. Flow diagram depicting pre-puriﬁcation steps required prior to determination of plasma estrogens with radioimmunoassay. Reproduced with permission from Ref.
[32].
Table 2
Mean levels (ML), detection limits and isotope used for the radioimmuno-assays (125I
or 3H) with respect to different methods used at different time periods for
measurement of postmenopausal estrogen levels in relation to aromatase inhibitor
therapies in our laboratory.
ML E2 E1 E1S References
15 pM 70 pM 400 pM
125I: 1.3 pM 8.7% 3H: 5.3 pM 7.6% 3H: 36.1 pM 9.0% [33]
125I: 2.6 pM 0.7% [31]
125I: 0.67 pM 4.4% 125I: 1.14 pM 1.6% 125I: 0.55 pM 0.14% [32]
Mean levels (ML) = consistent with expect based on steroid disposition [54,55].
The 125I radioimmunoassay was modiﬁed from original version by Dowsett and
colleagues [24].
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patients on treatment with such compounds need pre-puriﬁcation
with use of HPLC before radio immunoassaying [36].
Apart from differentiating between ﬁrst/second generation
aromatase inhibitors on the one hand as compared to the highly
potent third-generation compounds on the other side, plasma
estrogen measurements have been able to discriminate also
between highly potent third-generation compounds like anastroz-
ole and letrozole. Thus, two independent studies, both applying a
cross-over design, have conﬁrmed letrozole to be a more portent
plasma estrogen suppressor as compared to anastrozole [30,34],
consistent with tracer study ﬁndings [18]. Recently, data from
the same studies have been analyzed with respect to body mass
index (BMI). Conﬂicting data have challenged efﬁcacy of aromatase
inhibition for overweight/obese patients [37–39]; analyzing
plasma estrogen levels with these sensitive radioimmunoassay’s
[40,41] revealed slightly higher plasma estrogen levels related to
high BMI despite a similar degree of aromatase inhibition among
overweight as compared to normal-weight individuals [41].4. Tissue estrogen levels
Much interest has focused on issue estrogen levels since van
Landeghem [42] and others three decades ago reported breast
cancer tissue E2 levels a magnitude higher as compared to plasmalevels in postmenopausal women. Thus, issues have been raised
with respect to local estrogen synthesis by aromatization [43] as
well as de-conjugation of E1S [44]. Using our sensitive radioimmu-
noassay’s on tissue samples following HPLC puriﬁcation (Fig. 2), we
were able to detect tissue levels of E2 as well as E1 and E1S with
high degree of sensitivity [45]. Studying tumor tissue samples col-
lected before and during treatment with anastrozole or letrozole
[34,46], we conﬁrmed effective tissue estrogen suppression with
no evidence of ‘‘escape’’ for any single tumor. Further, studying tis-
sue estrogens across benign and malignant breast tissue [21], we
conﬁrmed elevated tissue to plasma E2 as well as E1 gradients; as
for benign tissue, the tissue to plasma ratio for E2 and E1 averaged
about 2 and 5, respectively. As for E1S, however, we found a tissue
to plasma gradient averaging 0.1 only, contrasting previous ﬁnd-
ings obtained by others with use of a direct radioimmunoassay
[47]. Interestingly, we conﬁrmed elevated tumor E2 levels in estro-
gen receptor positive but not in estrogen receptor negative tumors;
these elevated levels were found positively correlated to transcrip-
tional levels of the estrogen receptor as well as the reductive 17
hydroxy steroid dehydrogenase B7, but negatively correlated to
the oxidative B2 and B12 dehydrogenases [48]. However, tissue
E2 and E1 levels correlated even stronger to their corresponding
plasma estrogen concentrations [21,48]. These ﬁndings are in
agreement with the results from Professor Millers group revealing
the bulk of tumor tissue estrogens to have a plasma origin [49] and
the ﬁndings of Dunbier et al., reporting a strong correlation
between postmenopausal plasma E2 levels and tumor tissue
expression of estrogen-regulated genes [50].
Based on these ﬁndings, we proposed a new hypothesis, explain-
ing tissue to plasma hormone gradients based on physical–chemi-
cal properties for each individual compound [51]. Considering
unconjugated E2 and E1, these compounds are highly lipophilic,
explaining a high tissue to plasma concentration gradient. In con-
trast, E1S is a water-soluble conjugate. While the concentration of
plasma E1S exceeds the concentration of circulating E1 and E2 by
an average factor of 8 and 40, respectively [21], this is due to the fact
that most unconjugated E2 and E1 are converted into E1S which, on
the other hand, has a plasma clearance rate of only about 10% the
clearance rate of the unconjugated estrogens [52,53]. Our hypothe-
sis does not exclude local estrogen production; nor is it inconsistent
Fig. 2. Flow diagram depicting pre-puriﬁcation steps required prior to determination of tissue estrogens with radioimmunoassay. Reproduced with permission from Ref. [45].
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dehydrogenase activity to some degree may inﬂuence the ratio
between E2 and E1 in breast cancer tissue. However, the ﬁnding of
similar tissue to plasma estrogen gradients in pre- and postmeno-
pausal women despite substantial differences with respect to
plasma estrogen levels between these groups indicate tissue to
plasma equilibrium to be a rapid event [51]. Thus, local synthesis
would be of minor importance to local estrogen concentration, in
as much as estrogens synthesized locally would be quickly buffered
by the circulating pool of hormones.5. Discussion
Radioimmunoassay of plasma and tissue estrogen levels, in con-
cert with tracer studies, has contributed signiﬁcantly to our under-
standing of estrogen disposition. This has been mandatory to
development of aromatase inhibition, currently the major endo-
crine treatment option for postmenopausal breast cancer patients.
In contrast, there have been many publications reporting plasma
estrogen levels much higher than should be assumed based on the-
oretical calculations [54,55] and the need for caution with respect
to critically interpreting the results in the literature cannot be
overemphasized [55]. Further; recent studies applying radioimmu-
noassays have contributed to our understanding of estrogen dispo-
sition in general, including important topics like explaining
elevated tissue to plasma estrogen levels.Measurement of plasma estrogens in postmenopausal women,
due to their low levels, are time- and labor-dependent methods,
involving multiple steps such as chromatographic separation and
conversion [55]. The topic becomes complicated in particular when
measuring estrogen levels in patients on treatment with aromatase
inhibitors. For example, patients on treatment with letrozole, the
most potent aromatase inhibitor currently in clinical use, will fre-
quently have estradiol levels below the level of detectability. In
contrast, as estrone–sulfate circulates at much higher levels, this
steroid is usually in the detectable range in women receiving aro-
matase inhibitor therapy. Due to its high plasma level, E1S has been
considered a potential source for tissue estrogens through uptake
and hydrolysis [56]. While E1S may easily be hydrolyzed into
unconjugated hormones, its potential contribution to tissue estro-
gen levels, based on arguments raised above, may be questioned.
Whether plasma E1S may be a signiﬁcant contributor to tissue E2
or not, plasma E1S may be a good proxy parameter for estrogen
suppression with potent aromatase inhibitors as it exist at equilib-
rium with unconjugated E1 and E2 [21]. When considering tissue
estrogen measurements, this becomes even more demanding, in
general and requires pre-puriﬁcation of samples by use of HPLC.
Taken together, while reliable radioimmunoassays are available
and have played an important role in translational research, such
methods are too time- and labor-demanding to be functional for
routine purposes. While different liquid and gas chromatographic
methods over the years gradually have improved and should be
expected to replace use of radioimmunoassays for research and,
30 P.E. Lønning / Steroids 99 (2015) 26–31in particular, routine analysis in the future, it should be empha-
sized that, at this stage, there are only a few laboratories around
the world with methods documented to have a detection limit
allowing plasma estrogen assessment in patients on treatment
with aromatase inhibitors. While such methods are expected to
continuously improve, notably, they should be subject to the same
strict criteria documenting sensitivity and speciﬁcity in the low
concentration range with reproducibility similar to what has been
shown with respect to the most sensitive radioimmunoassay’s
[55].
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